publication venue for
- Extracorporeal Membrane Oxygenation for Graft Dysfunction Early After Heart Transplantation: A Systematic Review and Meta-analysis 2023
- Quantitative Data Collection to Enhance Use of a Heart Failure Self-care Application 2020
- Extra-Cardiac Disease Burden Contributes More Than Cardiac Disease Burden to Risk of Cardiovascular Outcomes in Patient with Preserved Ejection Fraction 2016
- Altered Executive Function in Older Heart Failure Patients at Hospital Discharge: New Data from the Montreal Cognitive Assessment Tool 2013
- Cognitive Function in Older Heart Failure Patients Is Similar to Older Patients Following Stroke 2012
- Prognostic Impact of an Ischemic Etiology of Chronic Heart Failure across the Spectrum of Ejection Fractions in the CHARM Program 2012
- Prognostic Utility of the Seattle Heart Failure Model To Predict Survival in Patients With Heart Failure 2012
- Canadian Heart Failure Patient and Caregiver Emotions 2011
- The Dutch Objective Burden Inventory – Validity and Reliability Testing in Canada 2010
- Use of 2-D Speckle Tracking Based Strain for Surveillance of Chemotherapeutic Induced Cardiotoxicity in a Pediatric Population 2010
- Symptoms of Anxiety and Depression in Heart Failure Patients and Their Caregivers 2009
- Uncertainty and Emotional Distress in Patients with Heart Failure and Their Primary Caregivers – A Novel Study 2009
- Health Related Quality of Life in I-PRESERVE Trial 2008
- Referral Patterns for Implantable Defibrillator Therapy: The Influence of Demographics, and Insurance Status 2008
- Aspirin and the Risk of Heart Failure Hospitalization in Patients with Atrial Fibrillation and a Prior History of Heart Failure: An ACTIVE-W Analysis 2006
- Intravenous Iron Sucrose in Anemic and Non-anemic Iron Deficient Patients with CHF: A Randomized, Controlled, Observer-blinded Intervention Study (FERRIC-HF) 2006
- Measurement of the Caregiving Experience in Caregivers of Patients with Heart Failure. A Review of Current Instruments and Recommendations for Future Research 2006
- The Baseline Characteristics of Patients Enrolled in the Irbesartan in Heart Failure with Preserved Systolic Function Trial Are Similar to Those in the Community but Differ from CHARM-Preserved 2006
- Implantable cardioverter-defibrillators in ventricular assist device-supported heart failure patients bridged to cardiac transplantation 2005
- Incidence and hospital death rates associated with new onset heart failure: A community-wide perspective 2005
- Left ventricular mass is lower with candesartan compared to placebo in patients with heart failure and preserved systolic function. Results from the CHARM echocardiographic substudy - CHARMES 2005
- Prevalence of chronotropic incompetence in a large pacemaker population: Effect of gender and age 2005
- Carvedilol produces sustained benefits over 12 years of follow-up 2004
- Early enalapril therapy in patients with left ventricular systolic dysfunction reduced cardiovascular morbidity and mortality at 15-years in SOLVD 2004
- Reduction in all-cause mortality and morbidity with candesartan in patients with chronic heart failure and systolic left ventricular dysfunction: results of the CHARM low EF trials 2004
- Left Ventricular Unloading Using Intra-aortic Entrainment Pumping Before Reperfusion Reduces Post-AMI Infarct Size.. S1071-9164(24)00316-6. 2024
- The International Consortium on Primary Graft Dysfunction: Redefining Clinical Risk Factors in the Contemporary Era of Heart Transplantation. 30:805-815. 2024
- Heart Failure Risk Under Covers: Sleeping With the Enemy. 30:449-451. 2024
- The “Weekend Effect” in Patients Admitted With Heart Failure: An Important Gap in Care?. 29:1367-1368. 2023
- Inconsistent Outcome Reporting in Heart Failure Randomized Controlled Trials. 29:425-433. 2023
- Can We Stop Reflexively Discontinuing Mineralocorticoid Antagonists for Patients With Heart Failure and Hyperkalemia?. 28:1464-1468. 2022
- Emerging Implantable-Device Technology for Patients at the Intersection of Electrophysiology and Heart Failure Interdisciplinary Care. 28:991-1015. 2022
- The Association Between Socioeconomic Status, Sex, Race / Ethnicity and In-Hospital Mortality Among Patients Hospitalized for Heart Failure. 28:697-709. 2022
- Biomarker Testing Considerations in the Evaluation and Management of Patients With Heart Failure: Perspectives From the International Federation of Clinical Chemistry and Laboratory Medicine Committee. 27:1456-1461. 2021
- Resting Heart Rate as an Important Predictor of Mortality and Morbidity in Ambulatory Patients With Heart Failure: A Systematic Review and Meta-Analysis. 27:349-363. 2021
- Predicting Survival in Patients With Heart Failure With an Implantable Cardioverter Defibrillator: The Heart Failure Meta-Score. 24:735-745. 2018
- Barriers to Goals of Care Discussions With Patients Who Have Advanced Heart Failure: Results of a Multicenter Survey of Hospital-Based Cardiology Clinicians. 23:786-793. 2017
- Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. 23:20-28. 2017
- Context Matters in Heart Failure Self-Care: A Qualitative Systematic Review. 20:448-455. 2014
- Heart Failure–Related Mortality and Hospitalization in the Year Following Admission to a Long-Term Care Facility: The Geriatric Outcomes and Longitudinal Decline in Heart Failure (GOLD-HF) Study. 19:468-477. 2013
- Baseline Plasma NT-proBNP and Clinical Characteristics: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Trial. 16:128-134. 2010
- Resource Use and Costs of Treatment With Anticoagulation and Antiplatelet Agents: Results of the WATCH Trial Economic Evaluation. 15:819-827. 2009
- Measurement of the Caregiving Experience in Caregivers of Persons Living With Heart Failure: A Review of Current Instruments. 13:577-587. 2007
- Plasma Matrix Metalloproteinase-9 Level Is Correlated With Left Ventricular Volumes and Ejection Fraction in Patients With Heart Failure. 12:514-519. 2006
- What Is the Economic Value of Digoxin Therapy in Congestive Heart Failure Patients? Results From the DIG Trial. 12:336-342. 2006
- Appropriateness of Spironolactone Prescribing in Heart Failure Patients: A Population-Based Study. 12:205-210. 2006
- The Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial: Rationale and Design. 11:576-585. 2005
- Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. 10:155-164. 2004
- The Warfarin and Antiplatelet Therapy in Heart Failure Trial (WATCH): rationale, design, and baseline patient characteristics. 10:101-112. 2004
- Early treatment with enalapril in patients with reduced ejection fractions protected against death and serious cardiovascular morbid events at 12 years in SOLVD. 9:s80. 2003
- Functional capacity in patients with congestive heart failure. 6:214-219. 2000
- HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approaches. 5:357-382. 1999
- Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and design. 5:276-282. 1999
- Factors influencing exercise performance in patients with left ventricular dysfunction. 4:159-167. 1998
- Strategies for patient recruitment into clinical trials. 4:235-236. 1998